Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PPDDX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2024222841A1 ADC55
|
|||||
| Synonyms |
ADC55
Click to Show/Hide
|
|||||
| Organization |
CSPC MEGALITH BIOPHARMACEUTICAL CO.,LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.85
|
|||||
| Structure |
|
|||||
| Antibody Name |
018 (CD33)
|
Antibody Info | ||||
| Antigen Name |
Myeloid cell surface antigen CD33 (CD33)
|
Antigen Info | ||||
| Payload Name |
(S)B19
|
Payload Info | ||||
| Therapeutic Target |
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)
|
Target Info | ||||
| Linker Name |
OXDc-VA-PAB (PEG)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
LD38
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth lnhibition value (TGl) |
100.2
|
%
|
Undisclosed | Undisclosed |
| Tumor Growth lnhibition value (TGl) |
108.6
|
%
|
Undisclosed | Undisclosed |
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal inhibitory Concentration (lC50) |
1.475
|
pM
|
CVCL_0064
|
Childhood acute monocytic leukemia
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 100.20% | High CD33 expression (CD33+++) | ||
| Method Description |
Investigated the antitumour effect of 0.1 mg/kg ADC in a CD33highCD123high MV-4-11 xenograft NOD SCID mice tumour model, D14.
|
||||
| In Vivo Model | CD123-high MV-4-11 xenograft NOD SCID mice tumour model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 108.60% | High CD33 expression (CD33+++) | ||
| Method Description |
Investigated the antitumour effect of 1mg/kg ADC in a CD33high MV-4-11 xenograft NOD SCID mice tumour model, D19.
|
||||
| In Vivo Model | CD33-high MV-4-11 xenograft NOD SCID mice tumour model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 1.475 pM | High CD33 expression (CD33+++) | ||
| Method Description |
Cytotoxicity of ADC to MV4-11 cells
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||